Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Indian Journal of Forensic Medicine & Toxicology
Saeed M Kabrah
Unknown Affiliation
Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
myc Gene and Cancer Variant Analysis and Network Interaction: An In-Silico Analysis Saeed M Kabrah; Talal Qadah; Arwa F Flemban
Indian Journal of Forensic Medicine & Toxicology Vol. 16 No. 1 (2022): Indian Journal of Forensic Medicine & Toxicology
Publisher : Institute of Medico-legal Publications Pvt Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37506/ijfmt.v16i1.17791

Abstract

The myc is a proto-oncogene that regulates the cellular process like cell growth, proliferation,metabolism, apoptosis and malignancy pathologies. myc deregulation occurs in several cancers andplays a significant role in disease development, metastatic potential, and therapeutic resistance. Drugtargeting myc in cancer remains highly desirable with substantial challenges, delaying the direct myctargeted drugs’s development. These drugs target the myc transcriptions deregulations in tumours cellby compound inhibiting the inducing of epigenetic silencing or regulation of G-quadruplex structureswithin the myc promoter. Proteins involved in myc’s post-translational modulation have been identifiedas significant surrogate targets for lowering myc activity downstream of aberrant cell stimulatorysignals.
MYC Gene Mutations as Causative Pathways for Development and Treatment of Hematological Malignancies Saeed M Kabrah
Indian Journal of Forensic Medicine & Toxicology Vol. 16 No. 1 (2022): Indian Journal of Forensic Medicine & Toxicology
Publisher : Institute of Medico-legal Publications Pvt Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37506/ijfmt.v16i1.17814

Abstract

MYC is a proto-oncogene with deregulation of >50% of human cancers. The dysregulation of MYC causetumorigenesis, cell growth and proliferation, cell growth, and apoptosis. Novel therapy approaches leadto the direct inhibition of the MYC gene by disruption of MYC/Max complex, MYC destabilization,inhibition of MYC translation and/or transcription. Cetuximab and panitumumab act on the epidermalgrowth factor receptor (EGFR). Cetuximab is an immunoglobin G1 isotype of a monoclonal antibodythat produces antibody-dependent cell-mediated. Panitumumab is an immunoglobulin G2 isotypemonoclonal antibody. This antibody acts on different site of EGFR with different degree of affinity.Genome-wide association studies e.g., TWAS determine the aggregate genotypes. Enhancer is cellspecificgene regulation that cluster for binding sites of a transcription factor with spatially coordinatedto control the expression of one or more specific target genes. In this review, we will summarize noveldrugs in targeting cancerous MYC in haematological malignancy.
Co-Authors Arwa F Flemban Talal Qadah